Table 1.

Baseline clinical and pathologic characteristics of cohort.

Number of patients evaluated	19
Age, median (range) in years	61 (45–80)
Duration of advanced disease, median (range) in years Location of metastasis	4.2 (1.4–28.3)
Bone	14 (73.7)
Visceral Race	15 (78.9)
White Prior therapy in adjuvant setting	19 (100.0)
Adjuvant endocrine	10 (52.6)
Adjuvant chemotherapy	9 (47.4)
Neither Prior therapy in advanced setting	8 (42.1)
n lines of endocrine-based therapy, median (range)	3 (1–5)
n lines of any therapy, median (range)	3 (1–6)
Tamoxifen	2 (10.5)
Letrozole	13 (68.4)
Anastrozole	4 (21.1)
Exemestane	13 (68.4)
Fulvestrant	13 (68.4)
CDK4/6i-containing	14 (73.7)
Everolimus-containing	12 (63.2)
Alpelisib-containing	1 (5.3)
Chemotherapy	7 (36.8)
Experimental agent	2 (10.5)